hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06297681 id: 2023-1-27-2 briefTitle: Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-01-30 date: 2025-12-31 date: 2024-03-07 date: 2024-03-07 name: Beijing Chao Yang Hospital class: OTHER name: Beijing Chuiyangliu Hospital name: Beijing Boren Hospital briefSummary: It is expected to include 40 patients with M-protein related cardiac disease. The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min). conditions: M-protein Related Cardiac Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin measure: Objective response rate (ORR) measure: 2-year PFS rate, progression free survival (PFS) measure: 2-year OS rate, overall survival (OS) measure: Duration of Relief (DOR) measure: Next treatment time (TTNT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297668 id: D5985C00008 briefTitle: A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C). overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2024-06-13 date: 2024-06-13 date: 2024-03-07 date: 2024-03-07 name: AstraZeneca class: INDUSTRY briefSummary: This study aims to assess the effect on total systemic exposure and to characterize exposure BGF MDI HFO with a spacer compared to without a spacer; also, to demonstrate that total systemic exposure of BGF when administered as MDI HFO with a spacer is not greater than BGF MDI HFA with a spacer. conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 42 type: ESTIMATED name: Treatment A: BGF MDI HFA name: Treatment B: BGF MDI HFO name: Treatment C: BGF MDI HFO name: AeroChamber Plus Flow-Vu spacer measure: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) of BGF MDI measure: Maximum Observed Concentration (Cmax) of BGF MDI measure: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) measure: Maximum Observed Concentration (Cmax) measure: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) measure: Time to Reach Maximum Observed Concentration (tmax) measure: Terminal Rate Constant (λz) measure: Half-life Associated with Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz) measure: Mean Residence Time of the Unchanged Drug in the Systemic Circulation from Zero to Infinity (MRTinf) measure: Apparent Total Body Clearance of Drug from Plasma After Extravascular Administration (CL/F) measure: Apparent Volume of Distribution at Steady State Following Extravascular Administration (Vz/F) measure: Number of Participants with Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Research Site city: Berlin zip: 14050 country: Germany lat: 52.52437 lon: 13.41053 facility: Research Site city: Harrow zip: HA1 3UJ country: United Kingdom lat: 51.57142 lon: -0.33371 hasResults: False
nctId: NCT06297642 id: TQB2928-AK105-Ib-01 briefTitle: TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-06 date: 2028-03 date: 2024-03-07 date: 2024-03-19 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors. conditions: Advanced Malignant Neoplasm studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 114 type: ESTIMATED name: TQB2928 injection name: Penpulimab measure: Dose limiting toxicity (DLT) measure: Adverse event rate measure: Objective response rate (ORR) measure: Complete response rate (CRR) measure: Disease Control Rate measure: Duration of Response measure: Progression-free Survival measure: Overall survival (OS) measure: Incidence of Anti-Drug antibody measure: Incidence of neutralizing antibodies measure: Peak time (Tmax) measure: Peak concentration (Cmax) measure: The area under the plasma concentration time curve from zero to after 24h (AUC0-24h) measure: Steady-state apparent volume of distribution (Vz/F) measure: Minimum plasma concentration at steady state (Cmin,ss) measure: Receptor Occupancy (RO%) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Science city: Beijing state: Beijing zip: 100021 country: China name: Ning Li, Doctor role: CONTACT phone: 15601395554 email: lining@cicams.ac.cn lat: 39.9075 lon: 116.39723 facility: Gansu Provincial Cancer Hospital city: Lanzhou state: Gansu zip: 730000 country: China name: Junfeng Jiang, Master role: CONTACT phone: 13893332604 email: 13893332604@163.com name: Yuhua Liu, Bachelor role: CONTACT phone: 15682892029 email: tianlujyx@163.com lat: 36.05701 lon: 103.83987 facility: Sun Yat-sen University Cancer Center city: Guangzhou state: Guangdong zip: 510000 country: China name: Qingqing Cai, Doctor role: CONTACT phone: 18376665396 email: caiqq@sysucc.org.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06297629 id: 2021-0636 id: NCI-2024-01689 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation overallStatus: NOT_YET_RECRUITING date: 2024-07-31 date: 2024-08-31 date: 2026-08-31 date: 2024-03-07 date: 2024-04-11 name: M.D. Anderson Cancer Center class: OTHER name: Astex Pharmaceuticals, Inc. briefSummary: To learn if ASTX727 given alone or in combination with donor lymphocyte infusion (DLI) can help to control certain types of hematological neoplasms (blood-based cancers) after a stem cell transplant. conditions: Allogeneic Stem Cell Transplantation studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 65 type: ESTIMATED name: ASTX727 name: Donor Lymphocyte Infusion measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Betul Oran, MD role: CONTACT phone: 713-745-2820 email: boran@mdanderson.org name: Betul Oran, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06297616 id: 18814 id: J3R-JE-YDAB type: OTHER domain: Eli Lilly and Company briefTitle: A Study of LY3841136 in Japanese Participants With Obesity or Overweight overallStatus: RECRUITING date: 2024-04-15 date: 2025-10-12 date: 2025-10-12 date: 2024-03-07 date: 2024-04-19 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to learn about the side effects of LY3841136 when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last about 28 weeks and may include up to 17 visits. conditions: Obesity conditions: Overweight studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 70 type: ESTIMATED name: LY3841136 name: Placebo measure: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136 measure: PK: Maximum Observed Concentration (Cmax) of LY3841136 measure: Pharmacodynamics (PD): Change From Baseline in Body Weight sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sumida Hospital status: RECRUITING city: Sumida-ku state: Tokyo zip: 130-0004 country: Japan role: CONTACT phone: 81356087276 name: Takuma Yonemura role: PRINCIPAL_INVESTIGATOR facility: Hakata Clinic status: RECRUITING city: Fukuoka zip: 812-0025 country: Japan role: CONTACT phone: 81922837701 name: Takashi Eto role: PRINCIPAL_INVESTIGATOR lat: 33.6 lon: 130.41667 hasResults: False
nctId: NCT06297590 id: 18795 id: J4T-MC-OLAA type: OTHER domain: Eli Lilly and Company id: 2024-510604-37-00 type: OTHER domain: EU Trial Number id: U1111-1302-6222 type: OTHER domain: Universal Trial Number briefTitle: A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-02 date: 2027-02 date: 2024-03-07 date: 2024-04-17 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.
The study will be comprised of two parts, A and B. Part B is optional, and participants from Part A may also have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. If conducted, each participant in Part B would receive 2 doses of either LY3954068 or placebo administered into the spinal fluid.
nctId: NCT06297577 id: MASH2024 briefTitle: Clinical Evaluation of Injectable Alb-PRF in the Management of Intrabony Defect in Stage-III Periodontitis Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-06-15 date: 2025-09-30 date: 2024-03-07 date: 2024-03-18 name: Cairo University class: OTHER briefSummary: Clinical Evaluation of Injectable Albumin Platelet Rich Fibrin Versus Platelet Rich Fibrin in the Management of Intra-bony Defect in Stage-III Periodontitis Patients.
will Albumin Platelet Rich Fibrin (Alb-PRF) as adjunct to minimally invasive surgical technique (MIST) be superior in terms of improvement in clinical parameters compared to the use of PRF with MIST. conditions: Intrabony Periodontal Defect studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Due to the type of intervention, only the outcome assessor and the statistician will be blinded whoMasked: OUTCOMES_ASSESSOR count: 26 type: ESTIMATED name: Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST) name: Platelet Rich Fibrin (PRF) combined with minimally invasive surgical technique (MIST) measure: Clinical attachment level (CAL) measure: Probing Depth (PD) measure: Radiographic Linear Defect Depth (RLDD) measure: Recession Depth (RD) measure: Post-operative Pain measure: Radiographic defect fill (RDF) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06297564 id: 07/3/9-2023/4 briefTitle: Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Assisted Reproductive Treatments overallStatus: COMPLETED date: 2022-09-01 date: 2024-01-01 date: 2024-01-01 date: 2024-03-07 date: 2024-03-07 name: New Valley University class: OTHER briefSummary: The aim of this study was to compare the clinical outcomes in progesterone primed endometrial protocol versus gonadotropin-releasing hormone antagonist protocol in women undergoing assisted reproductive treatments. conditions: Progesterone Primed Endometrial Protocol conditions: Gonadotropin Releasing Hormone Antagonist Protocol conditions: Assisted Reproductive Treatments studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ACTUAL name: Progesterone primed endometrial protocol name: Gonadotropin-releasing hormone antagonist protocol measure: The number of retrieved oocytes measure: Pregnancy rate sex: FEMALE minimumAge: 21 Years maximumAge: 40 Years stdAges: ADULT facility: New Valley University city: New Valley zip: 72511 country: Egypt hasResults: False
nctId: NCT06297551 id: SBU-AML-LSC id: IRB2023-00528 type: OTHER domain: Stony Brook University briefTitle: Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) overallStatus: RECRUITING date: 2024-03-05 date: 2025-05-31 date: 2025-05-31 date: 2024-03-07 date: 2024-03-07 name: Suhu Liu class: OTHER briefSummary: Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow and the most common form of acute leukemia in adults. Patient with AML have the shortest survival compared to other forms of leukemia. In the past 6 years, several new therapies have been approved. Biomarkers are in urgent need to guide therapeutic regimen selection in order to maximize the benefit of available therapies and minimize treatment toxicity. Current standard practice is to perform bone marrow biopsy at end of treatment cycle (each cycle around 28 days), and based on bone marrow finding, to decide further treatment plan. It is invasive and time consuming. The research we are proposing here is to investigate whether tracking leukemia stem cells (LSC) in peripheral blood during early treatment cycle may provide a non-invasive method to predict therapeutic outcome at end of treatment cycle. Our retrospective study have found that LSC fractional change, defined by two LSC markers, named CLL1 and CD45RA, is highly correlated with therapeutic outcome. Further more, CLL1 and CD45RA positive LSC fraction demonstrates a high concordance between bone marrow and peripheral blood, offering the opportunity to track CLL1 and CD45RA positive LSC fraction non-invasively in peripheral blood during treatment. This pilot study will allow us to decide whether testing CLL1 and CD45RA positive LSC in peripheral blood during leukemia treatment is feasible in clinical practice. This result will lay the foundation for designing future trials using CLL1 and CD45RA positive LSC fractional change to optimize therapeutic strategy for patients with AML. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry measure: Concordance between the relative fraction of Leukemia Stem Cells (LSC) vs Hematopoietic Stem Cells (HSC) and treatment response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stony Brook Cancer Center status: RECRUITING city: Stony Brook state: New York zip: 11794 country: United States name: Caterina Vacchi-Suzzi, PhD role: CONTACT phone: 631-728-7425 email: cancerclinicaltrials@stonybrookmedicine.edu name: Suhu Liu, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 40.92565 lon: -73.14094 hasResults: False
nctId: NCT06297538 id: GR-2021-12372323 briefTitle: Parkinson's Disease and Gamma-transcranial Alternating Current Stimulation overallStatus: RECRUITING date: 2023-04-29 date: 2024-10-29 date: 2026-04-29 date: 2024-03-07 date: 2024-03-07 name: Neuromed IRCCS class: OTHER name: Fondazione Policlinico Universitario Campus Bio-Medico name: I.R.C.C.S. Fondazione Santa Lucia briefSummary: Cortical-basal ganglia gamma oscillations are pathologically reduced in Parkinson's disease (PD) and the plasticity of the primary motor cortex (M1) is impaired. Enhancing gamma oscillations through transcranial alternating current stimulation (tACS), a non-invasive neurophysiological tool that modulates cortical rhythms, can restore this alteration. However, whether tACS-related normalization of M1 plasticity results in positive clinical effects is unknown. Motor learning is also impaired in PD and gamma oscillations play a relevant role in different forms of learning in humans. Nevertheless, whether motor learning abnormalities relate to reduced gamma oscillations in PD is another unclear issue. It can be hypothesized that gamma oscillations impairment in M1 contributes to altered motor control, plasticity and learning in PD. Accordingly, in this project, the authors intend to test whether gamma-tACS on M1 in PD patients ameliorates motor performance and learning, as objectively assessed with kinematic techniques. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 84 type: ESTIMATED name: gamma transcranial alternating current stimulation (tACS) name: sham transcranial alternating current stimulation (tACS) measure: Changes in bradykinesia features as objectively assessed by kinematic techniques measure: Changes in motor learning performance as objectively assessed by kinematic techniques sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Neuromed status: RECRUITING city: Pozzilli country: Italy name: Giulia Paparella role: CONTACT phone: 3384780752 lat: 41.51142 lon: 14.06252 hasResults: False
nctId: NCT06297525 id: STP938-201 briefTitle: Study of STP938 in Advanced Solid Tumours overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-12 date: 2027-05 date: 2024-03-07 date: 2024-03-08 name: Step Pharma, SAS class: INDUSTRY briefSummary: The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy.
The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Patients will be assigned to a dose level of STP938 (Phase 1a) or an expansion cohort (Phase 1b) at the time of their enrollment. primaryPurpose: TREATMENT masking: NONE count: 70 type: ESTIMATED name: STP938 measure: Safety and Tolerability measure: Area under the curve (AUC) of STP938 measure: Maximum plasma concentration (Cmax) measure: Time to reach maximum concentration (TMax) measure: Evaluation of preliminary clinical activity of STP938 measure: Evaluation of best overall response of STP938 measure: Evaluation of Duration of Response measure: Evaluation of Progression Free Survival measure: Change in serum CA125 (ovarian cancer only) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06297512 id: pGBM-WBRT/DOX2020 briefTitle: Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). overallStatus: RECRUITING date: 2022-12-09 date: 2027-11-09 date: 2028-03-09 date: 2024-03-07 date: 2024-03-07 name: Iacopo Sardi class: OTHER briefSummary: Glioblastoma (GBM) and diffuse intrinsic bridge gliomas (DIPG) only the most aggressive forms of cancer, and their prognosis remains bleak. Currently, the standard of treatment is TMZ concomitant with radiotherapy, and, at the end of combined treatment, as adjuvant therapy. In vitro and in vivo experimental studies have suggested that anthracyclines are effective antineoplastics for the treatment of gliomas. In patients with solid tumors treated with anthracyclines, continuous infusion administration compared with bolus administration has been shown to provide a better safety profile especially with regard to cardiotoxicity. Based on this evidence, this study aims to evaluate the safety and antitumor activity of combined treatment with Dox, WBRT (whole body radiotherapy), and TMZ in pediatric and young adult patients affected by GMB conditions: Glioblastoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Radiotherapy, Temozolomide, Doxorubicin measure: Evaluation prolonged Dox measure: Percentage of Withdrawal from the study rate measure: Percentage of SAEs measure: Mortality rate measure: Early discontinuation of dox treatment rate measure: Event-free survival (EFS), disease progression (PFS), and overall survival (OS) sex: ALL minimumAge: 3 Years maximumAge: 30 Years stdAges: CHILD stdAges: ADULT facility: Meyer Children's Hospital IRCCS status: RECRUITING city: Florence country: Italy name: Iacopo Sardi role: CONTACT email: iacopo.sardi@meyer.it lat: 43.77925 lon: 11.24626 hasResults: False
nctId: NCT06297499 id: IRB-22-07-4803 briefTitle: Ondansetron Use for Preventing Pruritus In Patients Undergoing Cesarean Section overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-08-01 date: 2024-12-01 date: 2024-03-07 date: 2024-03-12 name: Wayne State University class: OTHER briefSummary: Opioids are often added with a local anesthetic to enhance the duration and quality of spinal anesthesia for cesarean delivery patients. However, spinal opioids are associated with a wide variety of side effects such as nausea, vomiting, (N/V) and pruritus (itching). The occurrence of pruritus can vary between 30% and 100% making pruritus the most common side-effect of intrathecal opioids and this rate is even higher in pregnant patients. Pruritus may require treatment which can be ineffective or sometimes reverse the analgesic effect of the opioids. Ondansetron is a safe and very commonly used Serotonin receptor antagonist treatment for local anesthetic opioid-induced pruritus used in pregnancy. The effect of different administration times of ondansetron in reducing pruritus or N/V in cesarean section (CS) cases has not been extensively studied and thus, this prospective study can help guide future clinical management of side effects caused by spinal intrathecal morphine administration. conditions: Pruritus Caused by Drug studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized double-blinded trial primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The patient will be unaware of their grouping allotment. The outcomes assessor will be unaware of the patient grouping allotment. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: Ondansetron 8mg measure: Pruritus parameters in Post anesthesia Care Unit (PACU) measure: Pruritus severity in Post anesthesia Care Unit (PACU) measure: Pruritus parameters PACU measure: Pruritus severity PACU measure: Rescue Pruritus Treatment medication measure: Nausea PACU measure: Nausea Post PACU measure: Post-operative Pain measure: Peripheral oxygen saturation- Mother measure: Peripheral oxygen saturation- Infant measure: Heart rate- Mother measure: Heart rate- Infant measure: Blood pressure Mother measure: Blood pressure- Infant measure: Electrocardiogram (ECG ) Mother measure: ECG Infant sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Detroit Medical Center- Hutzel Women's Hospital city: Detroit state: Michigan zip: 48201 country: United States name: George M McKelvey, PhD role: CONTACT phone: 313-598-6036 email: gmckelve@dmc.org name: Justin Hruska, MD role: CONTACT phone: 402-432-0985 email: justinhruska1@gmail.com lat: 42.33143 lon: -83.04575 hasResults: False